Sertraline and Pregabalin Safety in First Trimester
Sertraline can be used during the first trimester with appropriate counseling about small absolute risks, while pregabalin should be avoided unless absolutely necessary due to insufficient safety data.
Sertraline in First Trimester
Safety Profile
SSRIs as a group, including sertraline, do not appear to be major teratogens 1. The most recent 2026 guidelines from multiple sources consistently support this position:
- Sertraline is specifically listed as a first-line choice for pharmacological treatment during pregnancy 2
- SSRIs carry a slight increased risk of spontaneous abortion, preterm birth, and low birth weight 3
- Small absolute risk of cardiac defects exists (approximately 2/1000 with paroxetine specifically, compared to baseline 1/1000), but evidence for sertraline is more reassuring 1
Specific Risks to Discuss
Cardiac malformations: While some studies suggest associations between first-trimester SSRI use and cardiac defects, a large population-based cohort study of nearly 1 million pregnant women found no clear link between first-trimester antidepressant use and cardiac malformations 4. When restricted to women with psychiatric diagnoses (controlling for confounding by indication), the risk becomes non-significant 5.
Third-trimester considerations: Persistent pulmonary hypertension of the newborn (PPHN) risk increases from 1.2/1000 unexposed to 3/1000 exposed infants 1. Poor neonatal adaptation syndrome occurs in up to 30% of exposed newborns but typically resolves within 2-3 days with supportive care 2.
Clinical Approach
The decision must weigh untreated maternal psychiatric illness against small absolute medication risks. Women who discontinued antidepressants during pregnancy showed significantly increased relapse rates compared to those who continued treatment 6.
Key counseling points:
- Benefits versus risks must be discussed, recognizing that OCD/depression can relapse following discontinuation 1
- If symptom-free for a long period, gradual withdrawal may be attempted with close monitoring for relapse 1
- Avoid paroxetine specifically due to slightly higher cardiac malformation risk 3, 2
Pregabalin in First Trimester
Safety Profile - Insufficient Evidence
Pregabalin should be avoided in the first trimester due to limited and conflicting safety data:
- A 2026 meta-analysis of 7 studies (701 exposed pregnancies) found no significant association with major congenital malformations (pooled OR 1.79,95% CI 0.80-3.99), but noted critical risk of bias and small sample sizes 7
- A 2026 European case-control study (170,126 registrants) found an association with ventricular septal defects (adjusted OR 2.5,95% CI 1.1-5.3), though based on only 37 exposed registrants 8
- A 2017 US Medicaid study found no increased risk after propensity score adjustment (RR 1.16,95% CI 0.81-1.67) 9
Critical Limitations
The evidence base is severely limited:
- Sample sizes remain extremely small across all studies
- High heterogeneity between studies (I² = 51%) 7
- Most studies have critical risk of bias 7
- Conflicting results make definitive conclusions impossible 8, 7, 9
Clinical Recommendation
Given the uncertainty and potential signal for cardiac defects, pregabalin should be avoided during the first trimester unless:
- No safer alternatives exist for the specific indication
- The maternal condition poses greater risk than potential fetal exposure
- The patient is fully informed of the limited and conflicting safety data
If pregabalin must be continued:
- Use the lowest effective dose
- Consider fetal echocardiography at 18-20 weeks to assess for cardiac anomalies
- Document detailed risk-benefit discussion and shared decision-making
Algorithm for Decision-Making
For sertraline:
- Assess severity of maternal psychiatric condition
- If moderate-to-severe: Continue/initiate sertraline with informed consent about small absolute risks
- If mild and symptom-free: Consider gradual taper with close monitoring
- Avoid paroxetine; prefer sertraline, escitalopram, or citalopram
- Plan for neonatal monitoring if continued into third trimester
For pregabalin:
- Reassess indication - is it absolutely necessary?
- Explore safer alternatives (other pain management strategies, non-teratogenic medications)
- If no alternatives: Detailed counseling about limited/conflicting data and potential cardiac risks
- If continued: Lowest effective dose + fetal cardiac monitoring
- Preferred approach: Discontinue before conception or immediately upon pregnancy recognition